Krabbe Disease
文献摘要
Clinical characteristics Individuals with Krabbe disease can present before age 12 months with infantile-onset disease characterized by extreme irritability, feeding difficulty, changes in muscle tone, and developmental delay. Infantile-onset Krabbe disease is characterized by apparent normal development in the first months followed by rapid severe neurologic deterioration with the average age of death of 24 months (range: age 8 months to 9 years). Most children are paraplegic by the second year of life. Later-onset Krabbe disease is characterized by onset of manifestations after age 12 to 36 months or as late as the seventh decade. Manifestations include gait changes, movement disorders, seizures, ocular manifestations, and neurologic decline. Later-onset Krabbe disease is variable in its presentation and disease course. Diagnosis/testing The biochemical diagnosis of Krabbe disease can be established in a symptomatic proband with findings of infantile-onset Krabbe disease, elevated psychosine levels in dried blood spot specimens, and identification of deficient galactocerebrosidase (GALC) enzyme activity in leukocytes. The molecular diagnosis of Krabbe disease can be established in a symptomatic proband with biallelic pathogenic variants in GALC identified by molecular genetic testing. The diagnosis can be established in an asymptomatic proband with low GALC enzyme activity, elevated psychosine on dried blood spot specimens on newborn screening (NBS), and biallelic pathogenic variants in GALC identified by molecular testing. Management Targeted therapy: Hematopoietic stem cell transplantation (HSCT) for those with predicted infantile-onset Krabbe disease who are presymptomatic or minimally symptomatic and show neuroimaging or neurophysiological evidence of disease. Treatment of manifestations: Supportive treatments for feeding including a gastrostomy tube with the goal of preventing aspiration pneumonia due to vomiting, gastroesophageal reflux, and dysphagia; laxatives to prevent constipation; baclofen, clonazepam, and botulinum toxin injections to help with spasticity; seizure treatment; gabapentin for neuropathic pain; positioning devices and physical therapy for contractures and to prevent hip subluxation and severe scoliosis; chest physical therapy, postural drainage, and suctioning for excessive airway secretions; bladder massage and intermittent catheterization for those with recurrent urinary tract infections; dark glasses for photophobia; eye lubricants and protective ointments for corneal ulcers; developmental and educational support; dental management for dental complications; family and social work support. Surveillance: Asymptomatic individuals should be monitored by a physician with experience in leukodystrophies; the frequency of comprehensive clinical assessment, brain MRI, blood psychosine measurement, and nerve conduction studies is based on risk for development of later-onset Krabbe disease. Assessment of symptomatic individuals includes evaluation of growth, nutrition, swallowing difficulties, chronic microaspiration, hydrocephalus, problems with gait and mobility, seizures, movement disorders, development, educational needs, behavioral issues, scoliosis, hip subluxation, visual changes, constipation, and respiratory issues at each visit. Physical medicine, occupational therapy, and physical therapy assessment are frequently needed due to rapid progression and changes in equipment needs. Swallowing study as needed; DXA scan to assess for osteopenia annually or as needed; ophthalmologic evaluation for decreased vision and corneal ulcerations per ophthalmologist. Agents/circumstances to avoid: Atypical antipsychotics and multiple medications for seizures can cause oversedation (affecting cognition, respiratory drive, and rate of neurologic decline). Routine childhood vaccinations can accelerate disease progression. Prolonged indwelling catheters for urinary retention can increase the risk of infection. Exposure to high or low temperatures, dehydration, untreated infections, and severe reflux can trigger seizures. Evaluation of relatives at risk: Newborns identified by either prenatal/neonatal evaluation because of a positive family history of Krabbe disease or an abnormal NBS result should undergo additional testing to identify those with infantile-onset Krabbe disease. Those with laboratory findings consistent with infantile-onset Krabbe disease are candidates for HSCT and should be immediately referred to an expert transplant center for further assessment. Genetic counseling Krabbe disease is inherited in an autosomal recessive manner. If both parents are known to be heterozygous for a GALC pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Once the GALC pathogenic variants have been identified in an affected family member, carrier testing for at-risk relatives and prenatal/preimplantation genetic testing are possible.